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Abstract: Chemotherapy-induced mucosal injury of the small intestine may interfere with the enzymes
and transporters responsible for the hydrolysis and absorption of dietary carbohydrates causing
diarrhoea, abdominal discomfort and pain. The aim of this study was to investigate the association
between the consumption of foods rich in FODMAPs (fermentable oligo-, di- and monosaccharides
and polyols) and gastrointestinal symptoms in patients receiving adjuvant therapy for colorectal
cancer. The patients (n = 52) filled in a 4-day food diary at baseline and during therapy and kept
a symptom diary. The intakes of FODMAP-rich foods were calculated as portions and the intakes
were divided into two consumption categories. Patients with high consumption of FODMAP-rich
foods had diarrhoea more frequently than those with low consumption (for lactose-rich foods the
odds ratio (OR) was 2.63, P = 0.03; and for other FODMAP-rich foods 1.82, P = 0.20). Patients with
high consumption of both lactose-rich and other FODMAP-rich foods had an over 4-fold risk of
developing diarrhoea as compared to those with low consumption of both (OR, 4.18; P = 0.02). These
results were confirmed in multivariate models. Conclusion: Consumption of lactose-rich foods results
in an increased risk of diarrhoea during adjuvant therapy for colorectal cancer, especially when the
consumption of other FODMAP-rich foods is also high.
Keywords: chemotherapy; colorectal cancer; diarrhoea; 5-fluorouracil; FODMAP; gastrointestinal
symptoms; hypolactasia; lactose intolerance
1. Introduction
Cytotoxic chemotherapy may damage the gastrointestinal tract mucosa and cause mucosal
inflammation, oedema, ulceration and tissue atrophy. Chemotherapy-associated gastrointestinal
toxicity often manifests as diarrhoea, abdominal discomfort and pain; it may also lead to treatment
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interruptions and even discontinuation [1,2]. A mucosal injury in the brush border of the small intestine
can interfere with the function of the enzymes and transporters that are responsible for hydrolysis
and absorption of dietary carbohydrates [3]. Unabsorbed carbohydrates end up in the colon, where
they are fermented by microbes to hydrogen, carbon dioxide and short chain fatty acids, which, when
abundant, act as osmotic laxatives and cause symptoms such as diarrhoea, flatulence and distension of
the abdomen [4,5].
Adjuvant 5-fluorouracil chemotherapy for colorectal cancer may be associated with reversible
hypolactasia and secondary lactose intolerance [6] but the efficacy of lactose-restriction in reducing
gastrointestinal toxicity during chemotherapy is unknown. Similarly, the effects of malabsorption
of other carbohydrates, such as fructose, on the symptoms evoked by chemotherapy remain to be
clarified. The fructose absorption capacity of the small intestinal epithelial cells is limited but can be
considerably enhanced by co-ingestion of glucose or galactose [4,7]. Fructose is increasingly found in
the Western diet [7].
A specific diet developed to alleviate symptoms of patients with the irritable bowel syndrome,
called the FODMAP-restriction diet, aims to reduce the intake of poorly absorbed (fermentable) oligo-,
di- and monosaccharides and polyols (FODMAPs), specifically fructans (inulin, fructo-oligosaccharides),
galacto-oligosaccharides, raffinose, lactose, fructose and polyols (sorbitol, mannitol, maltitol, xylitol
and lactitol) [8]. Lactose is considered as a FODMAP for patients with hypolactasia. FODMAPs are
quickly fermented in the proximal colon and are thought to be the principal cause of food-related
gastrointestinal symptoms in functional gastrointestinal disorders. A diet low in FODMAPs is
an effective dietary means to reduce these kinds of symptoms in these patients [9].
It is well-known that chemotherapy and radiotherapy exert toxic effects on the intestinal
mucosa [10]. Indeed, a non-controlled pilot-study demonstrated that a low FODMAP diet alleviated
symptoms and improved the quality of life in cancer patients with radiation-induced acute intestinal
injury [11], i.e., further evidence for a link between a high FODMAP intake and cancer-therapy-induced
diarrhoea, thus encouraging us to examine if a low FODMAP diet could also benefit patients
receiving chemotherapy.
The extent to which lactose and other poorly absorbed short chain carbohydrates contribute to
the gastrointestinal adverse effects evoked by 5-fluorouracil, the cornerstone for gastrointestinal cancer
treatments in both the adjuvant and metastatic setting, or other chemotherapeutic agents is unknown.
The objective of this study was to investigate whether the consumption of foods rich in FODMAPs
would be associated with gastrointestinal symptoms during adjuvant therapy for colorectal cancer.
2. Materials and Methods
2.1. Subjects and Study Design
The study was performed within the context of a prospective randomised factorial design
study (the LIPSYT study, ISRCTN98405441). The LIPSYT study focused on adverse events of
chemotherapy regimens that were given after surgery for colorectal cancer, chemotherapy-related
secondary lactose intolerance and involving a Lactobacillus rhamnosus GG intervention in an attempt to
reduce chemotherapy-associated adverse effects [6,12].
Briefly, the LIPSYT study compared two adjuvant 5-fluorouracil-based chemotherapy regimens,
the Mayo regimen and the simplified de Gramont regimen, as adjuvant treatments for colorectal cancer
and further assessed the effects of a probiotic Lactobacillus rhamnosus GG with or without guar gum
fibre on the adverse effects of chemotherapy [12] (Supplemental Figure S1). Briefly, the patients were
randomized by applying an open-label, 2 (chemotherapy) × 3 (supplements) factorial study design, to
receive adjuvant chemotherapies, the simplified de Gramont or the Mayo regimen and supplements,
Lactobacillus rhamnosus GG capsules (ATCC 53103, Valio Ltd., Helsinki, Finland), Lactobacillus rhamnosus
GG with guar gum fibre, or no supplements for 24 weeks. The minimization method with gender,
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tumour site and stage as prognostic factors were used to ensure that an equal number of participants
were allocated to the study groups.
Fifty-two (43%) out of the 120 patients who participated in the randomised adjuvant nutritional
intervention study could be included in the current FODMAP study (Figure 1).
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Figure 1. Flowchart showing the 120 patients originally included in the LIPSYT (Liitännäishoito:
Paksu- ja PeräsuoliSYöpäTutkimus, Finnish acronym) utritional intervention study and the 52 patients
examined in the FODMAP (fermentable, oligo-, di-, mono-saccharides and poly ls) st . Reasons for
exclusion are provided.
Patients were referred to the Helsinki University Hospital, Department of Oncology, for adjuvant
treatment of colorectal carcinoma. Inclusion criteria comprised age between 18 and 75 years and
histologically confirmed colorectal adenocarcinoma that was radically removed at surgery and rendered
free from all overt metastases. All patients had undergone one of the following surgical procedures:
right-sided hemicolectomy; left-sided hemicolectomy, Hartmann or sigma resection; anterior or
abdominoperineal resection; and total or subtotal colectomy (Table 1). All patients started a 24-week
adjuvant, 5-fluorouracil-based chemotherapy course. After the randomization, the groups consisted
either of the Mayo regimen (intravenous leucovorin 20 mg/m2 and a 3–5 min intravenous bolus of
5-fluorouracil, 370 to 425 mg/m2, on days 1–5 of the cycle, repeated six times at 4-week intervals) or
the simplified de Gramont regimen (a 2-h infusion of leucovorin 400 mg/m2, followed by a bolus of
400 mg/m2 5-fluorouracil bolus and a 46-h infusion of 3.03.6 g/m2 5-fluorouracil, repeated at 14-day
intervals during 24 weeks) [12]. Patients with rectal cancer (n = 20) received pelvic radiotherapy, either
preoperative radiotherapy (n = 6) or postoperative chemoradiation (n = 14). Preoperative radiotherapy
consisted of five 5-Gy fractions on weekdays. Postoperative chemoradiation was given to a cumulative
dose of 50.4 Gy in 1.8 Gy daily fractions for 5.5 weeks. The doses of 5-fluorouracil were reduced during
the cycles given during pelvic radiotherapy (cycles III and IV). The study protocol was approved by
the Institutional Review Board of Helsinki University Hospital and conforms to the provisions of the
Declaration of Helsinki. The trial was registered (identifier ISRCTN98405441). The study participants
provided written informed consent prior to initiation of the treatments.
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Table 1. Comparison of the baseline characteristics of the LIPSYT trial patients included in the present
study with the patients who were excluded.
Characteristic
Included Patients (n = 52) Excluded Patients (n = 68)
No. of Patients % No. of Patients % P-Value *
Age (years; median [range]) 59 35–74 60 31–76 0.41
Gender 1.00
Male 26 50 35 51
Female 26 50 33 49
Lactase deficiency status 0.26
Normolactasia 35 71 49 75
Borderline 5 10 2 3
Hypolactasia 9 18 14 22
Not available 3 3
Methane producer status 0.58
Producer 18 41 20 36
Non-producer 26 59 35 64
Not available 8 13
Cancer stage 0.44
Stage II 9 17 20 29
Stage III 36 69 40 59
Stage IV 7 14 8 12
Site of cancer 0.76
Colon 32 62 40 59
Rectum 20 38 28 41
Type of surgery 0.89
Right hemicolectomy 13 25 13 19
Left hemicolectomy or sigma
Resection 15 29 19 28
Rectum resection 20 38 29 43
Subtotal colectomy 4 8 7 10
Abdominal stoma 0.38
Yes 16 31 16 24
No 36 69 52 76
Time since surgery to study entry
(weeks; median [range]) 5 2.5–14 8 4–16 0.61
Chemotherapy 0.87
Mayo regimen 26 50 35 51
sLV5FU2 ** 26 50 33 49
Pelvic radiotherapy 0.17
Preoperative short course 6 12 2 3
Postoperative chemoradiation 14 27 22 32
None 32 61 44 65
Type of supplementation 0.82
Lactobacillus only 18 34 23 34
Lactobacillus + fibre 15 29 25 37
No supplements 19 37 20 29
* Chi2 test. Age at study entry and the time since surgery were compared with the Mann-Whitney U test. **
Simplified de Gramont reg.
We required that each FODMAP study participant kept a reliable food diary throughout the study,
underwent at least 3 months of chemotherapy and did not have metastatic disease that might interfere
with the evaluation of symptoms. A comparison of the baseline characteristics of the LIPSYT trial
patients [12] who were included in the FODMAP study and those who were excluded is provided in
Table 1.
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The patients filled in a 4-day food diary both before the beginning of the first adjuvant chemotherapy
cycle (baseline) and during the third chemotherapy cycle and kept a symptom diary of adverse effects,
including gastrointestinal complaints during the first and third month of adjuvant chemotherapy
administration (Supplemental Figure S1). The reasons for choosing the third therapy cycle as the
assessment point for symptoms and dietary intake were (1) only minor dose reductions were performed
after cycles I-II, (2) patients had received the treatment for 9–12 weeks, (3) dietary intake was not
affected by the results of the secondary lactose tolerance test (which was given to participants after
completion of the third chemotherapy cycle on week 12 and (4) secondary lactose intolerance had
stabilized and had been assessed.
2.2. Concurrent Medications, Assessment of Methane Production and Oral Lactose Tolerance Test
All necessary medication for appropriate treatment of concurrent diseases and treatment
associated adverse effects (for example, loperamide or octreotide for diarrhoea, antibiotics for
infection, metoclopramide and dexamethasone and granisetron/ondansetron/tropisetron as antiemetics)
were permitted.
Colonic methane production was measured before chemotherapy/intervention (at baseline)
as previously described [13]. Briefly, the categorization of subjects into methane producers and
non-producers was based on in vitro faecal fermentation results or on a breath test. No antibiotics,
enemas or laxatives were used for at least two weeks prior to sampling.
Lactose tolerance was evaluated at the baseline and after 12 weeks of adjuvant therapy (in the
middle of the therapy) by administering 50 g of lactose after a 12-h fast as previously described [6].
Blood glucose levels were measured at 20-min intervals for 40 min (hypolactasia, a blood glucose
level increase <1.1 mmol/L; borderline lactase deficiency, an increase of 1.1–1.6 mmol/L; no lactase
deficiency, an increase >1.6 mmol/L). The patients were informed about the results of the baseline
lactose test after completion of the first cycle at 4 weeks. Those with lactase deficiency at baseline were
instructed to consume either lactose-free or low-lactose foods from the beginning of the second cycle
onwards during the whole study. A second lactose tolerance test was carried out after the third month
of chemotherapy at 12 weeks; the results were provided to the patients when they had filled in their
food diaries and symptom diaries for the 3rd cycle.
2.3. Analysis of Food Diaries
Food diaries were analysed by a trained nutritionist (RH, who was blinded to other clinical
information) for the intake of lactose-rich foods and foods rich in other poorly absorbed short chain
carbohydrates i.e., fermentable oligo-, di- and monosaccharides and polyols (FODMAPs) [14,15].
Lactose-rich foods included in the analysis were liquid milk products (milk, buttermilk, yogurt, cream),
soured whole milk, curd, ice cream and porridge prepared in milk. Low-lactose or lactose-free milk
products were not included in the estimates. Lactose-rich foods were calculated in decilitres (dL).
FODMAP-rich food (calculated as portions) included in the estimate were breads, baked confectionary
such as buns, cakes and biscuits (1 portion corresponds to 1 piece), porridges prepared from wheat, rye
and barley (common dishes in Finland) (1 portion corresponds to 2 dL), muesli (1 portion corresponds to
1 dL), apples, pears, nectarines, apricots, peaches, plums (1 portion corresponds to 1 fruit), watermelon,
cherries, cauliflower, cabbage, peas, (1 portion corresponds to 1 dL), apple juice and pear juice
(1 portion corresponds to 2 dL). As far as we are aware, there is no computer software for the analysis
of the FODMAP content (other than lactose and fructose) of Finnish foods. Therefore, the intakes
of lactose-rich foods were calculated as decilitres and FODMAP-rich foods were calculated using
a portion as a measuring unit, thus considering the known and reliably self-reported FODMAPs.
FODMAP-rich foods were derived from the given references [12,13]. The data were categorized in two
or three consumption categories based on the intake of portions of FODMAPs or lactose rich foods
measured in decilitres per day.
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2.4. Assessment of Gastrointestinal Symptoms
The patients kept a diary of their gastrointestinal symptoms during chemotherapy and
chemotherapy-related adverse events were classified and graded every four weeks by an oncologist
(PÖ) according to the Common Toxicity Criteria of the National Cancer Institute of Canada scale,
version 2. The adverse events were graded according to the highest grade recorded during the first
month of adjuvant therapy administration (one 28-day cycle of the Mayo or two 14-day cycles of de
Gramont regimen) and according to the highest grade recorded during the third month of adjuvant
therapy (i.e., two periods). Thus, all patients included in the analysis received at least half of the
planned chemotherapy cycles.
2.5. Statistical Analysis
Chemo(radio)therapy related gastrointestinal symptoms (diarrhoea, constipation, vomiting,
flatulence, dyspepsia and stomatitis) of the highest intensity on a scale from grade 1 (mild) to grade 4
(life-threatening) were the primary variables examined in this study. The consumptions of lactose-rich
(dL/day) and FODMAP-rich foods (portions/day) were the primary explanatory variables. They were
considered as ordered data and were categorized according to median (above median consumption
(High) vs. below median consumption (Low)) and according to tertiles (highest, moderate vs.
lowest consumption). The analysis detected an interaction between lactose-rich (High vs. Low) and
FODMAP-rich (High vs. Low) consumptions in diarrhoea and flatulence. Therefore, the consumptions
of lactose-rich and FODMAP-rich foods were combined into one composite variable with four categories
(Low–Low, High–Low, Low–High and High–High). Two periods of both the gastrointestinal symptoms
(highest grade) and of the consumption of lactose-rich and FODMAP-rich foods were considered during
the FODMAP study. The association between the consumption of lactose-rich and FODMAP-rich foods
at the baseline vs. gastrointestinal symptoms during the first cycle and the same association during the
third cycle were not analysed separately. Instead, the associations between consumptions of lactose-rich
and FODMAP-rich foods vs. gastrointestinal symptoms were assessed using the generalized estimating
equations (GEE) analysis with binary logistic regression. The results are given as odds ratios (OR, with
a 95% confidence interval). The final models were adjusted for covariates. Treatment (simplified de
Gramont vs. Mayo regimen), Lactobacillus rhmannosus GG intervention (yes vs. no), fibre supplement
(yes vs. no), baseline lactose intolerance (yes vs. no), stoma (yes vs. no), methane producer (yes vs. no)
and postoperative radiotherapy (yes vs. no) were utilized as categorical covariates if their P-value was
<0.20 in the univariate analysis. Covariates were excluded one by one from the model if their P-value
was ≥0.20 after their introduction into the model. The GEE analysis with ANOVA was applied when
the consumption of lactose-rich foods during cycles I and III was compared between lactose intolerant
vs. lactose tolerant patients and the results are given as mean difference (95% confidence interval).
P-values <0.05 were considered significant. All tests were carried out as two-sided. Analyses were
performed using IBM SPSS Statistics for Windows (version 24.0, IBM Corp., Armonk, NY, USA).
3. Results
Patient characteristics are presented in Table 1. The characteristics of the patients and their
tumours of those who were included in the FODMAP study (n = 52) did not differ significantly from
those of the excluded LIPSYT patients in the nutritional intervention study (n = 68) (Table 1).
3.1. Dietary Intakes
Based on the food diaries, 47 (90%) out of the 52 subjects consumed lactose-rich foods, with
their median intake being 3.2 dL/day (range, 0–13.3) at baseline before cycle I and 2.9 dL/day (range,
0–17.3) during cycle III. As expected, lactose intolerant patients (those with hypolactasia or who had
a borderline finding in the lactose tolerance test at baseline) consumed less lactose-rich foods during
both periods than lactose tolerant patients [when considering both periods simultaneously, mean
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difference (95% CI) −2.0 dL/day (−3.5 to −0.6), P = 0.006]. All 52 subjects had FODMAP-rich foods in
their diet, with the median intake being 5.5 portions/day (range, 1.0–13.8) at baseline before cycle I and
5.4 portions/day (range 0–13.8) during cycle III.
3.2. Association of Dietary Intakes with Gastrointestinal Symptoms
The patients who consumed lactose-rich foods above the median value were twice as likely
to experience diarrhoea during chemo(radio)therapy than those consuming less than the median
(Table 2). A dose response was seen when the consumption of lactose-rich foods was divided in three
ordered consumption categories (the highest, moderate and the lowest). Patients who consumed the
greatest amounts of lactose-rich foods had the highest risk for developing diarrhoea during adjuvant
therapy, OR 4.23 (95% CI 1.37 to 13.04, P = 0.01) and those who consumed a moderate amount had
an intermediate risk, 2.31 (0.75–7.10, P = 0.14) as compared with those with the lowest consumption.
Flatulence was less frequent among those with a high intake of lactose-rich foods (Table 2).
No statistically significant differences in gastrointestinal symptoms were found in the univariate
analysis in patients who consumed FODMAP-rich foods above (High) or below (Low) the median
amount (Table 2) nor when the consumption of FODMAP-rich foods was divided into three ordered
consumption categories. During the treatment periods, the median intake of FODMAPs was 6.5 portions
in the above-median group (High) and 3.9 portions in the below-median (Low) group.
According to the composite variable analysis, patients who consumed both lactose-rich and
FODMAP-rich foods above the median (High) amount had a higher risk (OR 4.16) of developing
diarrhoea during chemo(radio)therapy in comparison to those whose intake of both lactose-rich
and FODMAP-rich foods was below the median (Low) amount (Table 3). Patients who consumed
lactose-rich foods above the median (High) but FODMAP-rich foods below the median (Low) had
a higher risk (OR 4.18) of developing diarrhoea, but also a significantly reduced risk for developing
flatulence during chemo(radio)therapy as compared to those whose intakes of both lactose-rich and
FODMAP-rich foods were below the median. Patients who consumed FODMAP-rich foods above the
median, but lactose-rich foods below the median, tended to have more than a doubled risk of diarrhoea
as compared to those whose intakes of both lactose-rich and FODMAP-rich foods were below the
median (Table 3). The background characteristics of the patients, such as the type of surgery or the
stage of cancer, did not explain the consumption of FODMAPs or lactose-rich foods; the results are
depicted in Supplemental Table S1.
3.3. Association of Patient Characteristics with Gastrointestinal Symptoms
In addition to the type of food consumed, also other factors were significantly associated with
diarrhoea during therapy in the univariable analyses and, therefore, these factors were included in
a multivariable analysis. In the final model, diarrhoea was explained by a high consumption of both
lactose-rich and FODMAP-rich foods and the presence of lactose intolerance at baseline, whereas if the
patient was a methane producer, this was a protective factor (Table 4). According to the final model
of flatulence, the protective factors were low consumption of FODMAP-rich foods combined to high
consumption of lactose-rich foods and the simplified de Gramont chemotherapy, whereas the presence
of lactose intolerance at the baseline increased the likelihood of flatulence.
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Table 2. Prevalence of chemo(radio)therapy-related gastrointestinal symptoms of at least mild intensity (Grade 1–4) during cycles I and III according to the consumption
of lactose-rich and FODMAP-rich foods in 52 colorectal cancer patients (univariate analysis).
Diarrhoea * Constipation Vomiting Flatulence Dyspepsia Stomatitis
n % n % n % n % n % n %
Consumption of lactose-rich foods †
Cycle I Low (n = 26) 6 23 6 23 15 58 12 46 4 15 19 73
High (n = 26) 15 58 6 23 17 65 6 23 7 27 14 54
Cycle III Low (n = 26) 11 42 8 31 16 62 8 31 6 23 11 42
High (n = 26) 14 54 4 15 14 54 4 15 1 4 19 73
High vs. Low ‡ OR95% CI
2.63
1.09–6.37
0.73
0.30–1.78
1.00
0.46–2.15
0.38
0.15–0.95
0.79
0.28–2.22
1.24
0.58–2.64
P-value 0.03 0.48 1.00 0.04 0.65 0.58
Consumption of FODMAP-rich foods §
Cycle I Low (n = 24) 9 38 5 21 14 58 8 33 3 13 16 67
High (n = 28) 12 43 7 25 18 64 10 36 8 29 17 61
Cycle III Low (n = 26) 10 38 8 31 15 58 4 15 4 15 11 42
High (n = 26) 15 58 4 15 15 58 8 31 3 12 19 73
High vs. Low ‡ OR95% CI
1.82
0.72–4.56
0.68
0.29–1.64
1.07
0.60–1.92
1.74
0.67–4.47
1.77
0.59–5.32
1.65
0.66–4.14
P-value 0.20 0.39 0.81 0.25 0.31 0.28
* Adverse events were assessed and graded according to the Common Toxicity Criteria of the National Cancer Institute of Canada scale version 2. † Low = below and High = above median
consumption. Cycle I median = 3.2 dL/day, Cycle III median 2.9 dL/day. ‡ Logistic regression analysis using generalized estimation equations (GEE)–method. § Low = below and High =
above median consumption. Cycle I median = 5.5 portions/day, Cycle III median 5.4 portions/day. OR = Odds ratio, CI = Confidence interval.
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Table 3. Prevalence of chemo(radio)therapy-related gastrointestinal symptoms of at least mild intensity (Grade 1–4) during cycles I and III according to the
combinations of lactose-rich and FODMAP-rich foods in 52 colorectal cancer patients (univariate analysis).
Consumption of Foods Rich in * Diarrhoea
† Constipation Vomiting Flatulence Dyspepsia Stomatitis
n % n % n % n % n % n %
Cycle I None, Lactose Low − FODMAP Low (n = 14) 3 21 3 21 7 50 7 50 1 7 10 71
Lactose High − FODMAP Low (n = 10) 6 60 2 20 7 70 1 10 2 20 6 60
Lactose Low − FODMAP High (n = 12) 3 25 3 25 8 67 5 42 3 25 9 75
Lactose High − FODMAP High (n = 16) 9 56 4 25 10 63 5 31 5 31 8 50
Cycle III None, Lactose Low − FODMAP Low (n = 15) 4 27 5 33 10 67 4 27 3 20 6 40
Lactose High − FODMAP Low (n = 11) 6 55 3 27 5 45 0 0 1 9 5 45
Lactose Low − FODMAP High (n = 11) 7 64 3 27 6 55 4 36 3 27 5 45
Lactose High − FODMAP High (n = 15) 8 53 1 7 9 60 4 27 0 0 14 93
Lactose High − FODMAP
Low vs. None ‡
OR
95% CI
P-value
4.16
1.25–13.81
0.02
0.89
0.26–3.07
0.85
0.76
0.33–1.77
0.53
0.10
0.02–0.54
0.01
0.93
0.16–5.57
0.94
0.95
0.28–3.25
0.94
Lactose Low − FODMAP
High vs. None ‡
OR
95% CI
P-value
2.59
0.77–8.71
0.13
0.80
0.22–2.86
0.73
0.85
0.32–2.28
0.75
1.35
0.45–3.99
0.59
2.16
0.41–11.21
0.36
1.34
0.40–4.43
0.63
Lactose High − FODMAP
High vs. None ‡
OR
95% CI
P-value
4.18
1.28–13.67
0.02
0.54
0.18–1.59
0.26
1.07
0.49–2.31
0.87
0.71
0.22–2.32
0.57
1.35
0.29–6.38
0.71
1.90
0.65–5.54
0.24
* Lactose Low, when the consumption of lactose-rich foods was below the median (3.2 dL/day during Cycle I, 2.9 dL/day during Cycle III) and Lactose High, when the consumption was
above the median. FODMAP Low, when the consumption of FODMAP-rich foods was below the median (5.5 portions/day during Cycle I, 5.4 portions/day during Cycle III) and FODMAP
High, when the consumption was above the median. † Adverse events were assessed and graded according to the Common Toxicity Criteria of the National Cancer Institute of Canada
scale version 2. ‡ Logistic regression analysis using generalized estimation equations (GEE)–method.
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Table 4. Results of multivariate analysis for chemo(radio)therapy-related diarrhoea and flatulence of at least mild intensity (Grade 1–4) during cycles I and III in 52
colorectal cancer patients.
Diarrhoea * Flatulence
OR 95% CI P-Value OR 95% CI P-Value
Consumption of foods
Lactose High − FODMAP Low † 10.08 0.85–119.2 0.07 0.09 0.01–1.10 0.06
Lactose Low − FODMAP High † 1.73 0.16–18.51 0.65 0.39 0.05–3.11 0.37
Lactose High − FODMAP High † 17.69 1.74–179.7 0.02 0.79 0.14–4.55 0.79
Covariates:
Chemotherapy regimen (simplified de Gramont vs. Mayo) - 0.09 0.02–0.51 0.01
Lactobacillus GG intervention (yes vs. no) - -
Fibre supplement (yes vs. no) - -
Baseline lactose intolerance (yes vs. no) 4.96 0.88–28.02 0.07 4.03 0.70–23.22 0.12
Presence of stoma (yes vs. no) - -
Methane-producer status (yes vs. no) 0.26 0.05–1.25 0.09 -
Postoperative chemoradiation (yes vs. no) - -
* Adverse events were assessed and graded according to the Common Toxicity Criteria of the National Cancer Institute of Canada scale version 2. † Lactose Low, when the consumption of
lactose-rich foods was below the median (3.2 dL/day during Cycle I, 2.9 dL/day during Cycle III) and Lactose High, when the consumption was above the median. FODMAP Low, when
the consumption of FODMAP-rich foods was below the median (5.5 portions/day during Cycle I, 5.4 portions/day during Cycle III) and FODMAP High, when the consumption was above
the median.
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4. Discussion
We investigated whether consumption of foods rich in poorly absorbed short chain carbohydrates
would be associated with gastrointestinal symptoms during adjuvant therapy for colorectal cancer.
We found a clinically relevant increase in the risk of diarrhoea in those patients who consumed
significant amounts of lactose-rich foods, especially if they also consumed FODMAP-rich foods
(multivariate analysis, Table 4).
To the best of our knowledge, no prior studies have assessed the effects of lactose-rich or
FODMAP-rich foods on gastrointestinal adverse effects attributable to chemotherapy. In one trial,
lactose restriction failed to prevent the diarrhoea induced by whole pelvis irradiation in cancer
patients [16]. Similarly, a reduction in the intake of dietary fibre and lactose exerted no effect on
the gastrointestinal side effects caused by local radiotherapy in prostate cancer patients [17]. These
two findings may not be surprising, since radiotherapy usually causes only local injury in the small
intestine, leaving most of the bowel intact.
It has been previously demonstrated that certain chemotherapeutic drugs, such as 5-fluorouracil,
increase intestinal permeability in mice [18]. In addition, a systematic review of clinical studies
concluded that chemotherapeutic drugs induce major changes in the composition of the gut microbiota
and these disruptions can contribute to the development of mucositis, i.e., diarrhoea [19]. It is of
interest that when mice were fed a high-FODMAP diet, this not only induced increased osmosis and
fermentation in gut, but also a major change in the microbiota of the animals [20]. Furthermore, the
level of the pro-inflammatory lipopolysaccharide (LPS) increased in lumen of gut in parallel with the
change in the microbial population when the FODMAP intake was high and this level was reduced
when FODMAP intake was low [20]. The clinical part of the same study [20] suggested that FODMAPs
might also increase faecal LPS levels in humans. Our working hypothesis was that chemotherapeutic
drugs cause a loss of intestinal barrier function, disrupt homeostasis of microbiota and disturb enzyme
production in the small bowel and thereby sensitize colorectal cancer patients to the osmotic and
fermentative effects of FODMAPs and lactose. Furthermore, a high intake of FODMAPs might further
worsen the mucositis by increasing the amount of the pro-inflammatory LPS compound in the gut.
In our previous study, the presence of hypolactasia during adjuvant therapy was associated
with both flatulence and diarrhoea [6]. In the present study, however, flatulence was less frequent
during adjuvant therapy in patients who consumed above the median levels of lactose-rich foods. This
seemingly contradictory finding may indicate that flatulence is more closely linked to hypolactasia
during adjuvant therapy, whereas diarrhoea is associated with the consumption of lactose-rich foods.
The results from the multivariable models were in line with this hypothesis, i.e., diarrhoea was more
strongly associated with the consumption of lactose-rich and FODMAP-rich foods than with presence
of lactose intolerance prior to the initiation of the treatments. Flatulence, on the other hand, was
more strongly linked with the presence of lactose intolerance at the baseline rather than with the
consumption of lactose-rich foods.
The limitations of the present study are the small patient numbers and that there might be some
inaccuracies in the calculation of the intakes of lactose-rich and FODMAP-rich foods. We tried our
best to take the latter limitation into account by using categories estimated as decilitres or portions
instead of exact grams of intake. In addition, inaccuracies due to the incompleteness of the dietary
analysis software were avoided. However, a limitation of this way of assessing the FODMAP content
is that the specifics of the diet are lost and there is a risk of either underestimating or overestimating
the FODMAP content. For example, the designation of FODMAP foods into our categorization was
not comprehensive [21]; those FODMAP foods that tended to be minor parts of usually prepared
meals were rather poorly reported as recipes and consequently we were not able to count them reliably
from food diaries. However, we are confident that we captured the most relevant FODMAP foods
consumed by our participants. Another limitation of the present study in assessing the role of these
carbohydrates in causing gastrointestinal symptoms is that the dietary habits may change when the
patient’s symptoms worsen. Inter-subject variations in the outcomes were quite large and p-values
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relatively high. Despite of these limitations, the findings of the present study encourage design and
conduction of ten new randomized studies on low FODMAP diet in this particular patient group.
Indeed, a randomized multi-centre phase II study led by one researcher from our group is underway
where these patients are recommended to consume a low FODMAP diet.
It is noteworthy that different means of restricting caloric intake may also offer protection from
chemotoxicity. Based both on animal experiments and the first human pilot studies, it seems that
short-term fasting may reduce the severity of chemotoxicity [22]. However, more robust human trials
are urgently needed to clarify the pros and cons of this approach in a clinical setting.
Diarrhoea may be a dose-limiting factor in cytotoxic therapy; it is often the major toxic adverse
effect of regimens containing fluoropyrimidines (i.e., 5-fluorouracil) and irinotecan and can be
life-threatening [1]. In a randomised trial in colorectal cancer patients, Ravasco et al. demonstrated that
an appropriate manipulation of the diet based on regular foods by individual dietary counselling could
be beneficial in reducing the gastrointestinal symptoms evoked by radiotherapy [23]. Furthermore,
a low-FODMAP diet reduced radiotherapy-induced gastrointestinal symptoms in a non-controlled
trial [11]. In line with these data, our results suggest that a low-FODMAP diet may alleviate diarrhoea
also during adjuvant chemotherapy for colorectal cancer.
5. Conclusions
In conclusion, patients who consumed high amounts of lactose and other FODMAPs had more
diarrhoea during adjuvant therapy of colorectal cancer as compared to patients who consumed low
amounts of lactose and FODMAPs. A diet low in lactose and FODMAPs may thus be a means to
prevent and/or to alleviate the severity of the diarrhoea occurring during adjuvant therapy. This
hypothesis warrants further evaluation in a prospective randomised study.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6643/12/2/407/s1,
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